248 related articles for article (PubMed ID: 26446698)
1. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
3. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
4. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
[TBL] [Abstract][Full Text] [Related]
7. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
[TBL] [Abstract][Full Text] [Related]
8. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
9. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Leu L; Baribeault D
J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
[TBL] [Abstract][Full Text] [Related]
11. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
12. Effect of mannitol on acute kidney injury induced by cisplatin.
Bégin AM; Monfette ML; Boudrias-Dalle É; Lavallée E; Samouelian V; Soulières D; Chagnon M; Fournier MA; Letarte N; Adam JP
Support Care Cancer; 2021 Apr; 29(4):2083-2091. PubMed ID: 32862356
[TBL] [Abstract][Full Text] [Related]
13. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
El Hamamsy M; Kamal N; Bazan NS; El Haddad M
Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
16. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
Morgan KP; Buie LW; Savage SW
Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
[TBL] [Abstract][Full Text] [Related]
17. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
18. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
19. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
20. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Dimery IW; Legha SS
J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]